Histogenics Corporation (HSGX) Raised to “Buy” at Zacks Investment Research
Histogenics Corporation (NASDAQ:HSGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm presently has a $2.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 4.17% from the company’s previous close.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
HSGX has been the subject of several other research reports. ValuEngine cut shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Canaccord Genuity reissued a “buy” rating on shares of Histogenics Corporation in a research note on Thursday, May 11th. Finally, HC Wainwright set a $4.00 price target on shares of Histogenics Corporation and gave the company a “buy” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $5.25.
Shares of Histogenics Corporation (NASDAQ HSGX) traded up 1.59% on Thursday, hitting $1.92. The company’s stock had a trading volume of 63,894 shares. Histogenics Corporation has a one year low of $1.45 and a one year high of $3.75. The stock has a 50-day moving average price of $1.83 and a 200 day moving average price of $1.75. The firm’s market cap is $43.18 million.
Histogenics Corporation (NASDAQ:HSGX) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. Equities research analysts predict that Histogenics Corporation will post ($1.09) EPS for the current year.
A hedge fund recently raised its stake in Histogenics Corporation stock. Sabby Management LLC increased its stake in shares of Histogenics Corporation (NASDAQ:HSGX) by 15.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,095,422 shares of the biotechnology company’s stock after purchasing an additional 150,531 shares during the period. Sabby Management LLC owned approximately 5.31% of Histogenics Corporation worth $1,895,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.08% of the company’s stock.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.